Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing University, Nanjing, China.
Department of Cardiothoracic Surgery, Jinling Hospital, Nanjing Medical University, Nanjing, China.
Cell Death Dis. 2021 Jul 30;12(8):752. doi: 10.1038/s41419-021-04031-w.
Alternative splicing (AS) is an important event that contributes to posttranscriptional gene regulation. This process leads to several mature transcript variants with diverse physiological functions. Indeed, disruption of various aspects of this multistep process, such as cis- or trans- factor alteration, promotes the progression of colorectal cancer. Therefore, targeting some specific processes of AS may be an effective therapeutic strategy for treating cancer. Here, we provide an overview of the AS events related to colorectal cancer based on research done in the past 5 years. We focus on the mechanisms and functions of variant products of AS that are relevant to malignant hallmarks, with an emphasis on variants with clinical significance. In addition, novel strategies for exploiting the therapeutic value of AS events are discussed.
选择性剪接 (AS) 是一种重要的事件，有助于转录后基因调控。这一过程导致了具有不同生理功能的几种成熟的转录变体。事实上，破坏这一多步过程的各个方面，如顺式或反式因子改变，会促进结直肠癌的进展。因此，针对 AS 的某些特定过程可能是治疗癌症的有效治疗策略。在这里，我们根据过去 5 年的研究，提供了与结直肠癌相关的 AS 事件概述。我们重点介绍与恶性特征相关的 AS 变体产物的机制和功能，特别强调具有临床意义的变体。此外，还讨论了利用 AS 事件治疗价值的新策略。
